Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBU NASDAQ:GRML NASDAQ:REPL NASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.97+1.8%$1.97$0.73▼$3.54$193.91M2.271.27 million shs226,589 shsGRMLGreenland Mines Ltd. Common Stock$0.50+1.5%$0.51$0.12▼$3.91$61.01M7.613.38 million shs1.09 million shsREPLReplimune Group$3.15+9.6%$5.89$1.50▼$13.24$261.33M0.123.85 million shs1.37 million shsSLGLSol-Gel Technologies$75.39+2.2%$79.07$6.57▼$97.97$211.83M1.1635,407 shs2,174 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences+3.21%-7.21%-0.52%+19.14%+124.76%GRMLGreenland Mines Ltd. Common Stock-3.03%+10.86%-4.62%+96.85%+194.12%REPLReplimune Group+14.80%+11.67%-65.87%-59.00%-71.33%SLGLSol-Gel Technologies-2.43%+4.02%-7.16%+11.86%+1,569.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.97+1.8%$1.97$0.73▼$3.54$193.91M2.271.27 million shs226,589 shsGRMLGreenland Mines Ltd. Common Stock$0.50+1.5%$0.51$0.12▼$3.91$61.01M7.613.38 million shs1.09 million shsREPLReplimune Group$3.15+9.6%$5.89$1.50▼$13.24$261.33M0.123.85 million shs1.37 million shsSLGLSol-Gel Technologies$75.39+2.2%$79.07$6.57▼$97.97$211.83M1.1635,407 shs2,174 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences+3.21%-7.21%-0.52%+19.14%+124.76%GRMLGreenland Mines Ltd. Common Stock-3.03%+10.86%-4.62%+96.85%+194.12%REPLReplimune Group+14.80%+11.67%-65.87%-59.00%-71.33%SLGLSol-Gel Technologies-2.43%+4.02%-7.16%+11.86%+1,569.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 2.75Moderate Buy$8.00307.12% UpsideGRMLGreenland Mines Ltd. Common Stock 1.00SellN/AN/AREPLReplimune Group 1.60Reduce$4.7551.03% UpsideSLGLSol-Gel Technologies 2.33Hold$110.0045.92% UpsideCurrent Analyst Ratings BreakdownLatest GRML, SLGL, REPL, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/22/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CRBUCaribou Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026REPLReplimune Group Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold4/13/2026REPLReplimune Group BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform4/13/2026REPLReplimune Group Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$11.00 ➝ $2.004/13/2026REPLReplimune Group Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$13.00 ➝ $2.004/13/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$19.00 ➝ $2.004/13/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight4/13/2026REPLReplimune Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Sell(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$11.16M17.38N/AN/A$1.31 per share1.50GRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/A$0.13 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ASLGLSol-Gel Technologies$19.39M10.92N/AN/A$8.19 per share9.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$148.12M-$1.59N/AN/AN/A-1,327.40%-78.40%-58.68%5/14/2026 (Estimated)GRMLGreenland Mines Ltd. Common Stock-$10.55M-$0.32N/AN/AN/AN/A-137.58%-126.00%N/AREPLReplimune Group-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%5/28/2026 (Estimated)SLGLSol-Gel Technologies-$6.13M-$2.23N/AN/AN/A-31.60%-24.29%-18.73%5/22/2026 (Estimated)Latest GRML, SLGL, REPL, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q4 2026REPLReplimune Group-$0.73N/AN/AN/A$0.95 millionN/A5/22/2026Q1 2026SLGLSol-Gel Technologies-$1.84N/AN/AN/A$0.90 millionN/A5/14/2026Q1 2026CRBUCaribou Biosciences-$0.33N/AN/AN/A$2.21 millionN/A3/19/2026Q4 2025SLGLSol-Gel Technologies$0.39-$1.07-$1.46-$1.06$6.50 million$0.70 million3/5/2026Q4 2025CRBUCaribou Biosciences-$0.33-$0.28+$0.05-$0.28$1.96 million$3.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A5.715.71GRMLGreenland Mines Ltd. Common StockN/A95.0295.02REPLReplimune Group0.335.605.60SLGLSol-Gel TechnologiesN/A4.374.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%GRMLGreenland Mines Ltd. Common Stock20.07%REPLReplimune Group92.53%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences8.54%GRMLGreenland Mines Ltd. Common Stock9.90%REPLReplimune Group5.20%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10098.68 million90.26 millionOptionableGRMLGreenland Mines Ltd. Common Stock5121.24 million109.24 millionN/AREPLReplimune Group21082.57 million78.28 millionOptionableSLGLSol-Gel Technologies502.81 million941,000No DataGRML, SLGL, REPL, and CRBU HeadlinesRecent News About These CompaniesSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Up 48.9% in AprilApril 28, 2026 | marketbeat.comSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 31.7% in MarchApril 14, 2026 | marketbeat.comSol-Gel Technologies (NASDAQ:SLGL) Shares Down 0.6% - Time to Sell?April 14, 2026 | marketbeat.comSol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary SharesMarch 23, 2026 | quiverquant.comQSol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten OfferingMarch 23, 2026 | globenewswire.comSol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue EstimatesMarch 19, 2026 | zacks.comSol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025March 19, 2026 | globenewswire.comThis Under-the-Radar Stock Has Surged 1,300% Over the Past YearMarch 13, 2026 | finance.yahoo.comSol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last yearFebruary 11, 2026 | finance.yahoo.comSol-Gel Technologies (SLGL) price target increased by 120.00% to 112.20February 4, 2026 | msn.comOpaleye Management Inc. Buys 1,151 Shares of Sol-Gel Technologies (NASDAQ:SLGL) StockJanuary 24, 2026 | insidertrades.comSol-Gel Technologies: Downgrading To 'Hold' As Success Relies On Upcoming Q4 CatalystJanuary 18, 2026 | seekingalpha.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 8,638 SharesJanuary 1, 2026 | insidertrades.comInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $10,831.60 in StockDecember 30, 2025 | insidertrades.comWe Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business GrowthDecember 29, 2025 | finance.yahoo.comWhy Sol-Gel Technologies Ltd.’s (SLGL) Stock Is Down 5.05%December 27, 2025 | aaii.comASol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Buys 2,735 SharesDecember 20, 2025 | insidertrades.comSol-Gel Technologies updates clinical pipeline following Phase 1b resultsDecember 17, 2025 | msn.comSol-Gel halts studies for rare disease therapy after trial setbackDecember 17, 2025 | msn.comSol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier DiseaseDecember 17, 2025 | markets.businessinsider.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $95,432.44 in StockDecember 4, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026Bitcoin and Big Tech Rally as Risk Appetite Returns, Even With Ceasefire UncertaintyBy Jessica Mitacek | April 21, 2026The Drone Disruptor: Kratos Stock Seeks a Higher Altitude By Jeffrey Neal Johnson | April 8, 2026The PDT Rule Is On Its Way Out: 5 Stocks That Stand to Benefit the MostBy Ryan Hasson | April 20, 2026GRML, SLGL, REPL, and CRBU Company DescriptionsCaribou Biosciences NASDAQ:CRBU$1.96 +0.04 (+1.81%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Greenland Mines Ltd. Common Stock NASDAQ:GRML$0.50 +0.01 (+1.53%) As of 10:39 AM EasternGreenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.Replimune Group NASDAQ:REPL$3.14 +0.28 (+9.58%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Sol-Gel Technologies NASDAQ:SLGL$75.39 +1.62 (+2.19%) As of 10:50 AM Eastern This is a fair market value price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
